Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • More than 90 percent students of Academically.ai passed Australian Pharmacy Council KAPS examination

    Academically.ai is delighted to announce that more than 93% of its students have successfully passed the Australian Pharmacy Council KAPS examination on their first attempt. The team is extremely proud of its students' achievements and feels honored to have them as a part of its academic community.

  • Novel Immunotherapy Agent Safe, Shows Promise Against High-Risk Prostate Cancers

    A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.

  • Johnson & Johnson offers USD 8.9 Bn to settle talc suits

    Johnson & Johnson has reached a deal in the long-running lawsuit against its talc-based products. Thousands of people have sued the company over the past decade, claiming the products - including its iconic baby powder - caused cancer.

  • Cipla signs pact with Novartis Pharma for Galvus, anti diabetics

    Cipla Limited has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) on 10th April 2023 to manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from 1st January 2026.

  • In-Cosmetics Global 2023

    In-Cosmetics Global 2023 Exhibition & Conference was held in Barcelona, Spain at the Fira Barcelona Gran from 28th to 30th March 2023.

  • Granules Consumer Health Inc., inaugurates its Packaging Facility in the U.S.

    Granules India inaugurated and launched its packaging facility through its Granules Consumer Health (GCH) step-down subsidiary which is located in Manassas, Virginia, US. The facility is over 79,000 square feet and is equipped with packaging lines and clean rooms to package and ship prescription and over-the-counter products across the U.S. market. The facility recently received US FDA approval with zero 483 observations.

  • No Custom duty on import of medicines used in rare diseases, says India

    Government has given full exemption from custom duty on import of medicines used in rare diseases. The Central Government has given full exemption from basic customs duty on all drugs and Food for Special Medical Purposes imported for personal use for treatment of all Rare Diseases listed under the National Policy for Rare Diseases 2021 through a general exemption notification.

  • Government to set up 270 pharmacies in Eastern Railways

    Healthcare facilities such as pharmacies and collection centres for pathology laboratories will be established at 270 stations in the Eastern Railway zone by the end of this year.

    “In a bid to spread healthcare facilities to the remotest corner of its network, the Eastern Railway has awarded the contract for setting up healthcare-focused multi-utility stores at 270 stations for a period of five years,” Arora told reporters.

  • PCI invites Government faculty for panel empanelment of Exit Exam

    Pharmacy council of India is preparing for the exit exam for Diploma pharmacy. PCI invites Government faculty for panel empanelment of Exit Exam.

    PCI (Pharmacy council of India) said in a notification that this is to bring to kind information that Exit Examination for Diploma in Pharmacy has to be conducted. Faculty from Government and Government Aided colleges are hereby informed to fill the form for being considered as an expert.

  • Lupin receives tentative approval from USFDA for Obeticholic Acid Tablets

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Subscribe to Pharma News